N-(3,4-dimethoxyphenylethyl)-3,4-dimethoxybenzenesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3,4-dimethoxyphenylethyl)-3,4-dimethoxybenzenesulfonamide
• 英文别名: N-(3,4-dimethoxyphenethyl)-3,4-dimethoxybenzenesulfonamide；N-[2-(3,4-dimethoxyphenyl)ethyl]-3,4-dimethoxybenzenesulfonamide
• 化学式: C₁₈H₂₃NO₆S
• 分子量: 381.45
• InChiKey: CASIIKXOPZVDDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  91.5
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3,4-二甲氧基苯磺酰氯 、 3,4-二甲氧基苯乙胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以52%的产率得到N-(3,4-dimethoxyphenylethyl)-3,4-dimethoxybenzenesulfonamide
  参考文献：
  名称：

  Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies

  摘要：

  Phosphodiesterase 4 (PDE4) inhibitors have emerged as a new strategy to treat asthma and other lung inflammatory diseases. Searching for new PDE4 inhibitors, we previously reported the discover of LASSBio-448, a sulfonamide with potential to prevent and reverse pivotal pathological features of asthma. In this paper, two novel series of sulfonamide (6a-6m) and sulfonyl hydrazone (7a-7j) analogues of LASSBio-448 have been synthetized and evaluated for selective inhibitory activity toward cAMP-specific PDE4 isoforms. From these studies, we have identified 7j (LASSBio-1632) as a new anti-asthmatic lead-candidate associated with selective inhibition of PDE4A and PDE4D isoenzymes and blockade of airway hyper-reactivity (AHR) and TNF-alpha production in the lung tissue. In addition, it was able to relax guinea pig trachea on non-sensitized and sensitized animals and showed great TGI permeability. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112492

文献信息

• Restraining the flexibility of the central linker in terameprocol results in constrained analogs with improved growth inhibitory activity
  作者：Sherman Si Han Ho、Mei Lin Go

  DOI：10.1016/j.bmcl.2013.09.014

  日期：2013.11

  The semi-synthetic lignan terameprocol inhibits the transcription of several inflammatory and oncogenic genes and has been evaluated for its anti-cancer properties. Here we investigated the effect of restricting the flexibility of the carbon linker connecting the terminal rings of terameprocol on its growth inhibitory activity. Conformational restriction was explored by introducing unsaturation, inserting polar entities with limited flexibility and cyclization of the connecting linker. Twenty three compounds were synthesized and evaluated on a panel of malignant human cells. The most promising compounds were those with non-polar linkers, as seen in butadiene 1a and the cyclized benzylideneindane analog 7. Both compounds were more potent than terameprocol on pancreatic BxPC-3 cells with GI(50) values of 3.4 and 8.1 mu M, respectively. Selected isomers of 1a (E,E) and 7 (Z) adopted low energy bent conformations that mimicked the low energy conformer of terameprocol. It is tempting to propose that conformational similarity to terameprocol may have contributed to their good activity. The scaffolds of 1a and 7 should be further investigated for their anticancer potential. (c) 2013 Elsevier Ltd. All rights reserved.
• Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies
  作者：Isabelle Karine da Costa Nunes、Everton Tenório de Souza、Italo Rossi Roseno Martins、Gisele Barbosa、Manoel Oliveira de Moraes Junior、Millena de Melo Medeiros、Sheyla Welma Duarte Silva、Tatiane Luciano Balliano、Bagnólia Araújo da Silva、Patrícia Machado Rodrigues Silva、Vinicius de Frias Carvalho、Marco Aurélio Martins、Lidia Moreira Lima

  DOI：10.1016/j.ejmech.2020.112492

  日期：2020.10

  Phosphodiesterase 4 (PDE4) inhibitors have emerged as a new strategy to treat asthma and other lung inflammatory diseases. Searching for new PDE4 inhibitors, we previously reported the discover of LASSBio-448, a sulfonamide with potential to prevent and reverse pivotal pathological features of asthma. In this paper, two novel series of sulfonamide (6a-6m) and sulfonyl hydrazone (7a-7j) analogues of LASSBio-448 have been synthetized and evaluated for selective inhibitory activity toward cAMP-specific PDE4 isoforms. From these studies, we have identified 7j (LASSBio-1632) as a new anti-asthmatic lead-candidate associated with selective inhibition of PDE4A and PDE4D isoenzymes and blockade of airway hyper-reactivity (AHR) and TNF-alpha production in the lung tissue. In addition, it was able to relax guinea pig trachea on non-sensitized and sensitized animals and showed great TGI permeability. (C) 2020 Elsevier Masson SAS. All rights reserved.